UNSPSC 51433902: Amlodipine

This classification denotes a calcium channel blocker with the molecular formula C20H25ClN2O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1J444QC288, chemically known as 3,5-pyridinedicarboxylic acid, 2-((2-aminoethoxy)methyl)-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-, 3-ethyl 5-methyl ester but generally known as amlodipine, which bears US NIH Compound Identifier 2162. Amlodipine most often comes in base, benzenesulfonate, besilate, besylate, and maleate forms.

UNSPSC 51433902 Amlodipine is a Commodity code encompassing specific pharmaceutical active ingredients procured by state and local health systems, emergency services, and pharmacy benefit programs. State and local governments buy amlodipine and related cardiovascular medications as part of Advanced Life Support medication supply contracts, generic multi-source pharmaceutical agreements serving institutional health facilities, and direct-to-manufacturer pharmacy initiatives aimed at improving cost management and supply chain efficiency. The issuing bodies span city fire rescue departments, state health and human services commissions, and multistate cooperative purchasing alliances administering contracts on behalf of dozens of participating agencies across multiple states. Recent solicitations show amlodipine being procured alongside other cardiovascular agents (labetalol, diltiazem, adenosine, epinephrine) as part of bundled medication line-item purchasing rather than as a standalone drug.

Activity is concentrated in Florida and Minnesota, with cross-state coordination through cooperative purchasing vehicles. The City of Tampa's Purchasing Department issued an IFB (Bid No. 26-P-00188) for Advanced Life Support Medications on April 24, 2026, with a response deadline of April 8, 2026 and an estimated contract value of $40,000.00, including a Small Local Business Enterprise sheltered-market set-aside with a 5 percent bid discount not to exceed $10,000. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP for Generic Multi Source Pharmaceuticals and OTC Products on January 20, 2026, due March 26, 2026, establishing multi-vendor contracts effective July 1, 2026 across participating state and local government facilities including Oregon. The Texas Health and Human Services Commission posted an RFI on April 3, 2026 exploring direct-to-manufacturer prescription fulfillment strategies, signaling upstream procurement redesign that could reshape how amlodipine and other generics are sourced at the state level.